New trends in hepatitis C management;Nouvelles tendances dans la prise en charge de l'hépatite C

Presse Medicale

Volumn 39, Issue 4, 2010, Pages 446-451

  Mallet, Vincent ^a   Vallet Pichard, Anaïs ^a   Pol, Stanislas ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4' CHLORO 4 (4 HYDROXY 1 PIPERIDINYLCARBONYL)BIPHENYL 2 YLMETHOXY] 2 FLUOROPHENYL] 1 CYCLOHEXYL 5 BENZIMIDAZOLECARBOXYLIC ACID; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BOCEPREVIR; CILUPREVIR; CPG 10101; ERYTHROPOIETIN; HEMOGLOBIN; INTERFERON; INTERNAL RIBOSOME ENTRY SITE INHIBITOR; ISATORIBINE; JTK 109; NS 3 4A; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POLYMERASE INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED RNA POLYMERASE INHIBITOR; TARIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE;

ANEMIA; ANXIETY; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SYNTHESIS; GASTROINTESTINAL TOXICITY; HAIR LOSS; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; LYMPHOCYTE; MALAISE; MALE HOMOSEXUAL; MORBIDITY; MORTALITY; NONHUMAN; RNA INTERFERENCE; SHORT SURVEY; SIDE EFFECT; TERATOGENICITY; THYROID DISEASE; VIRAL CONTAMINATION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG CARRIERS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER NEOPLASMS; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RIBAVIRIN; WORLD HEALTH;

EID: 77951138710     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.12.037     Document Type: Short Survey

References (39)

1. Thein H.H., Yi Q., Dore G.J., Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008, 48:418-431.
2. Bruno S., Stroffolini T., Colombo M., Bollani S., Benvegnu L., Mazzella G., et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579-587.
3. Mallet V., Gilgenkrantz H., Serpaggi J., Verkarre V., Vallet-Pichard A., Fontaine H., et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008, 149:399-403.
4. Veldt B.J., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., Zeuzem, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147:677-684.
5. Luxon B.A., Grace M., Brassard D., Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002, 24:1363-1383.
6. Medina J., Garcia-Buey L., Moreno-Monteagudo J.A., Trapero-Marugan M., Moreno-Otero R. Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003, 60:135-143.
7. Zeuzem S., Welsch C., Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003, 23(Suppl 1):23-28.
8. Jacobson I.M., Brown R.S., McCone J., Black M., Albert C., Dragutsky M.S., et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007, 46:982-990.
9. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
10. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-α-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
11. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
12. Kamal S.M., El Tawil A.A., Nakano T., He Q., Rasenack J., Hakam S.A., et al. Peginterferon {α}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005, 54:858-866.
13. Muir A.J., Bornstein J.D., Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265-2271.
14. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
15. Shiffman M.L., Hofmann C.M., Contos M.J., Luketic V.A., Sanyal A.J., Sterling R.K., et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999, 117:1164-1172.
16. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954-960.
17. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086-1097.
18. Sanchez-Tapias J.M., Diago M., Escartin P., Enriquez J., Romero-Gomez M., Barcena R., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006, 131:451-460.
19. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44:97-103.
20. Zeuzem S., Pawlotsky J.M., Lukasiewicz E., von Wagner M., Goulis I., Lurie Y., et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005, 43:250-257.
21. Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Sola R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357:124-134.
22. Jensen D.M., Freilich B., Andreone P., DiBisceglie A., Brandao-Mello C.E., Reddy K.R., et al. Pegylated interferon alfa-2A (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon α-2B (12KD)/RBV: Final efficact and safety outcomes of the repeat study. Hepatology 2007, 46:291A-292A.
23. Fried M.W., Jensen D.M., Rodriguez-Torres M., Nyberg L.M., Di Bisceglie A.M., Morgan T.R., et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon α-2a and ribavirin. Hepatology 2008, 48:1033-1043.
24. Shiffman M.L., Salvatore J., Hubbard S., Price A., Sterling R.K., Stravitz R.T., et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin α. Hepatology 2007, 46:371-379.
25. Rustgi V., Nelson D., Balan V., Sulkowski M., Lambiase L., Davis G., et al. A Phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection. Journal of Hepatology 2006, 44:S50-S60.
26. Hinrichsen H., Benhamou Y., Wedemeyer H., Reiser M., Sentjens R.E., Calleja J.L., et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004, 127:1347-1355.
27. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
28. Reiser M., Hinrichsen H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005, 41:832-835.
29. Forestier N., Reesink H.W., Weegink C.J., McNair L., Kieffer T.L., Chu H.M., et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007, 46:640-648.
30. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I., Kauffman R., McNair L., et al. Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. Journal of Hepatology 2008, 48:S4-S.
31. Dusheiko G.M., Hezode C., Pol S., Goeser T., Bronowicki J.P., Bourliere M., et al. Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: Further interim analysis results of the PROVE2 study. Journal of Hepatology 2008, 48:S26-S.
32. Schiff E., Poordad E., Jacobson I., Flamm S., Bacon B., Lawitz E., et al. Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness. Journal of Hepatology 2008, 48:S46-S.
33. Kwo P., Lawitz E., McCone J., Schiff E., Vierling J., Pound D., et al. Interim results from HCV sprint-1: RVR/EVR from phase 2 study of boceprevir plus pegintrontm (peginterferon alfa-2b)/ribavirin in treatmentnaive subjects with genotype-1 CHC. Journal of Hepatology 2008, 48:S372-S.
34. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Muh U., Welker M., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
35. Roberts S., Cooksley G., Dore G., Robson R., Shaw D., Berns H., et al. Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients. Gastroenterology 2007, 132:A779-A.
36. Villano S., Raible D., Harper D., Chandra P., Bazisotto L., Bichier G. Phase 1 evaluation of antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with different pegylated interferons in the treatment-naive patients with chronic HCV. Hepatology 2007, 46. 815A.
37. McHutchison J.G., Bacon B.R., Gordon S.C., Lawitz E., Shiffman M., Afdhal N.H., et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007, 46:1341-1349.
38. Horsmans Y., Berg T., Desager J.P., Mueller T., Schott E., Fletcher S.P., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42:724-731.
39. Gish R.G., Arora S., Reddy K.R., Nelson D.R., O'Brien C., Xu Y., et al. Virological response and safety outcomes in therapy-ndive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. Journal of Hepatology 2007, 47:51-59.